Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20354)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Mean Normalized Growth Rate Inhibition Value | Increased Fraction Dead |
|---|---|---|---|---|
| HCC1395 | BMS-265246 | 0.1 | 0.1856 | 0.05910 |
| HCC1395 | BMS-265246 | 0.316227766017 | 0.0528 | 0.02664 |
| HCC1395 | BMS-265246 | 0.316227766017 | 0.0196 | 0.04103 |
| HCC1395 | BMS-265246 | 0.316227766017 | 0.0113 | 0.07428 |
| HCC1395 | BMS-265246 | 1.0 | -0.1116 | 0.03886 |
| HCC1395 | BMS-265246 | 1.0 | -0.0313 | 0.01711 |
| HCC1395 | BMS-265246 | 1.0 | 0.1308 | 0.08280 |
| HCC1395 | BMS-265246 | 3.16227766017 | -0.1776 | 0.06003 |
| HCC1395 | BMS-265246 | 3.16227766017 | -0.0954 | 0.05118 |
| HCC1395 | BMS-265246 | 3.16227766017 | -0.1157 | 0.10754 |
| HCC1395 | BMS-265246 | 10.0 | -0.1669 | 0.03743 |
| HCC1395 | BMS-265246 | 10.0 | -0.2349 | 0.08866 |
| HCC1395 | BMS-265246 | 10.0 | -0.1682 | 0.06263 |
| HCC1395 | Ulixertinib | 0.001 | 1.2160 | 0.00955 |
| HCC1395 | Ulixertinib | 0.001 | 0.8694 | 0.00792 |
| HCC1395 | Ulixertinib | 0.001 | 1.0432 | -0.00495 |
| HCC1395 | Ulixertinib | 0.003162278 | 1.1011 | -0.00239 |
| HCC1395 | Ulixertinib | 0.003162278 | 0.9085 | -0.00034 |
| HCC1395 | Ulixertinib | 0.003162278 | 0.9553 | -0.00436 |
| HCC1395 | Ulixertinib | 0.01 | 0.7915 | -0.00640 |
| HCC1395 | Ulixertinib | 0.01 | 1.1853 | 0.00057 |
| HCC1395 | Ulixertinib | 0.01 | 0.8754 | 0.05397 |
| HCC1395 | Ulixertinib | 0.031622777 | 0.8394 | 0.01699 |
| HCC1395 | Ulixertinib | 0.031622777 | 0.7811 | -0.00420 |
| HCC1395 | Ulixertinib | 0.031622777 | 0.8304 | 0.02985 |